Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Why it matters: Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue from new transcatheter mitral and tricuspid ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Stifel upgrades Edwards Lifesciences to Buy, citing TAVR growth potential and FDA label expansion in 2025. Edwards' Critical Care sale and focus on structural heart could drive higher valuation ...

The latest conference call transcript from Edwards Lifesciences Corporation has revealed a remarkable fourth quarter ...

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...

William Blair analyst Margaret Kaczor acknowledges that while Edwards Lifesciences’ TAVR growth has potential, more evidence is needed to confirm it will reach the high end of 2025 guidance ...